File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients

TitleInterim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients
Authors
Issue Date2019
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The International Liver Congress 2019, Vienna, Austria, 10-14 April 2019. Abstracts Book in Journal of Hepatology, 2019, v. 70 n. 1, Suppl., p. e130 How to Cite?
DescriptionPoster Presentation - no. LBO-06
Persistent Identifierhttp://hdl.handle.net/10722/275330
ISSN
2023 Impact Factor: 26.8
2023 SCImago Journal Rankings: 9.857
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMa, XL-
dc.contributor.authorLalezari, J-
dc.contributor.authorNguyuen, T-
dc.contributor.authorBae, Ho-
dc.contributor.authorSchiff, ER-
dc.contributor.authorFung, S-
dc.contributor.authorYuen, RMF-
dc.contributor.authorHassanein, T-
dc.contributor.authorHann, HW-
dc.contributor.authorElkhashab, M-
dc.contributor.authorDieterich, D-
dc.contributor.authorSulkowski, M-
dc.contributor.authorKwo, P-
dc.contributor.authorNahass, R-
dc.contributor.authorAgarwal, K-
dc.contributor.authorRamji, A-
dc.contributor.authorPark, J-
dc.contributor.authorRavendhran, N-
dc.contributor.authorChan, S-
dc.contributor.authorWeilert, F-
dc.contributor.authorHan, SH-
dc.contributor.authorAyoub, W-
dc.contributor.authorGane, E-
dc.contributor.authorJacobson, I-
dc.contributor.authorBennett, M-
dc.contributor.authorHuang, Q-
dc.contributor.authorYan, R-
dc.contributor.authorHuey, V-
dc.contributor.authorRuby, E-
dc.contributor.authorLiaw, S-
dc.contributor.authorColonno, R-
dc.contributor.authorLopatin, U-
dc.date.accessioned2019-09-10T02:40:23Z-
dc.date.available2019-09-10T02:40:23Z-
dc.date.issued2019-
dc.identifier.citationThe International Liver Congress 2019, Vienna, Austria, 10-14 April 2019. Abstracts Book in Journal of Hepatology, 2019, v. 70 n. 1, Suppl., p. e130-
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/275330-
dc.descriptionPoster Presentation - no. LBO-06-
dc.languageeng-
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatology-
dc.relation.ispartofInternational Liver Congress 2019-
dc.titleInterim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients-
dc.typeConference_Paper-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authorityYuen, RMF=rp00479-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0618-8278(19)30230-0-
dc.identifier.hkuros304582-
dc.identifier.hkuros307201-
dc.identifier.volume70-
dc.identifier.issue1, Suppl.-
dc.identifier.spagee130-
dc.identifier.epagee130-
dc.identifier.isiWOS:000463481700231-
dc.publisher.placeNetherlands-
dc.identifier.issnl0168-8278-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats